A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS7415 Tablets in Patients With Advanced Malignant Tumors
Latest Information Update: 07 Mar 2024
At a glance
- Drugs HRS 7415 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 15 Apr 2022 New trial record